Stockwinners Market Radar for August 07, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:58 EDT Ciner Resources lowers FY17 maintenance capital expenditures view to $10M-$12M - Previous FY17 maintenance capital expenditures view was $12M-$15M. Sees FY17 cxpansion capital expenditures $17M-$20M compared to previous estimate of $23M-$28M. Sees FY17 soda ash volume sold to remain flat to 2016 compared to the previous estimate of 1% to 3% growth; sees international prices to be up 3% to 5%; and domestic pricing to be flat to down 3%.

18:23 EDT S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices - S&P SmallCap 600 constituent CoreSite Realty (COR) will replace NeuStar (NSR) in the S&P MidCap 400, and Vonage Holdings (VG) will replace CoreSite Realty in the S&P SmallCap 600 effective prior to the open on Thursday, August 10. NeuStar is being acquired by a private investment group led by Golden Gate Capital in a deal expected to be completed tomorrow pending final closing conditions.

18:12 EDT Ellington Financial reports estimated book value per share $19.55 on July 31 - Ellington Financial announced that its estimated book value per common share as of July 31 was $19.55, or $19.27 on a diluted basis.

18:01 EDT Community Healthcare raises dividend to 39.25c - Community Healthcare Trust announced that its Board of Directors has increased its common stock cash dividend for the quarter ended June 30. This dividend, in the amount of 39.25c per share, is payable on September 1 to shareholders of record on August 28. This dividend rate equates to an annualized dividend of $1.57 per share. Community Healthcare Trust Incorporated has increased its dividend every quarter since its Initial Public Offering.

17:54 EDT On The Fly: After Hours Movers - UP AFTER EARNINGS: Cutera (CUTR), down 18.4%... Iteris (ITI), up 14.2%... MDC Partners (MDCA), up 12.3%... Rapid7 (RPD), up 12.1%... Twilio (TWLO), up 11.2%... Manitowoc (MTW), up 9.3%... 2U (TWOU), up 8%... Luminex (LMNX), up 7.7%... LendingClub (LC), up 7.3%... Viewray (VRAY), up 5.3%... Inphi (IPHI), up 2.7%. ALSO HIGHER: Fibrogen (FGEN), up 55.7% after it said that pamrevlumab met its primary efficacy endpoint in a Phase 2 study. DOWN AFTER EARNINGS: Tenet (THC), down 10.1%... Depomed (DEPO), down 10.6%... Plains GP Holdings (PAGP), down 9.4%... Sunrun (RUN), down 9.3%... Plains All American (PAA), down 8.7%... Avis Budget (CAR), down 8.5%... InnerWorkings (INWK), down 5.7%... Arena Pharmaceuticals (ARNA), down 3.9%... Airgain (AIRG), down 2.9%... Compass Minerals (CMP), down 2.7%. ALSO LOWER: Endo (ENDP), down 4.4% after it reached agreements to resolve virtually all known U.S. mesh product liability claims.

17:47 EDT Marriott sees FY17 incentive fees up mid-single digits

17:41 EDT Raytheon awarded $227.5M government contract modification - Raytheon Co., McKinney, Texas, was awarded a $227.5M modification to contract W909MY-16-D-0003 for horizontal technology integration; second generation forward looking infrared and independent thermal viewers; and assemblies for the servo electronics unit. Work locations and funding will be determined with each order, with an estimated completion date of Sept. 25, 2018. U.S. Army Contracting Command, Aberdeen Proving Ground, Aberdeen, Maryland, is the contracting activity.

17:38 EDT MedEquities Realty Trust acquires facilities from AAC Holdings for $25M - AAC Holding (AAC) has signed a definitive agreement to sell its two standalone outpatient facilities and two sober living facilities in Las Vegas, Nevada and Arlington, Texas for $25M in cash to MedEquities Realty Trust (MRT). Concurrently with the sale, the Company will lease the facilities from MedEquities pursuant to a 15-year triple-net lease at an initial lease rate of 8.75%. AAC expects to deploy the proceeds to pay down borrowings on its revolving credit facility and fund its de novo activities. The transaction is expected to close by August 11, 2017, subject to customary closing conditions. The AAC facilities that are included in the sale are the two standalone outpatient treatment facilities in Las Vegas, Nevada and Arlington, Texas

17:32 EDT MedEquities Realty acquires facilities from Trust AAC Holdings for $25M - AAC Holding (AAC) has signed a definitive agreement to sell its two standalone outpatient facilities and two sober living facilities in Las Vegas, Nevada and Arlington, Texas for $25M in cash to MedEquities Realty Trust (MRT). Concurrently with the sale, the Company will lease the facilities from MedEquities pursuant to a 15-year triple-net lease at an initial lease rate of 8.75%. AAC expects to deploy the proceeds to pay down borrowings on its revolving credit facility and fund its de novo activities. The transaction is expected to close by August 11, 2017, subject to customary closing conditions. The AAC facilities that are included in the sale are the two standalone outpatient treatment facilities in Las Vegas, Nevada and Arlington, Texas.

17:17 EDT CoreSite Realty to replace NeuStar in S&P 400 at open on 8/10 - NeuStar is being acquired by a private investment group led by Golden Gate Capital in a deal expected to be completed on 8/8 pending final closing conditions.

17:16 EDT Reata doses first patient in Phase 3 CARDINAL trial - Reata Pharmaceuticals announced the enrollment of the first patient in the Phase 3 portion of the CARDINAL trial of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome. The purpose of this study is to determine the safety and efficacy of bardoxolone in Alport syndrome patients and to determine if Alport syndrome patients experience improvements in kidney function compared to placebo.

17:11 EDT Tallgrass Energy Partners acquires Powder River oil gathering system - Tallgrass Energy Partners announced that through its subsidiary Tallgrass Midstream, LLC it has closed on the acquisition of Outrigger Energy LLC's crude oil gathering system in the Powder River Basin for approximately $36M, subject to potential adjustments specified in the purchase agreement. The acquired assets include approximately 34 miles of gathering lines and approximately 150,000 acres dedicated on a long-term fee-based contract. Tallgrass estimates approximately $7M in additional capital expenditures for the remainder of 2017 on the Outrigger system. As a result of the acquisition, Tallgrass Interstate Gas Transmission, LLC intends to abandon by sale to TMID an underutilized segment of its system from Labonte, Wyo., to Guernsey, Wyo. The abandonment, which is subject to approval by the Federal Energy Regulatory Commission, will have no adverse effect on TIGT's firm transportation customers.

17:04 EDT Willbros Group names Jeffrey Kappel CFO, S. Brett Luz CAO - Willbros Group announced the promotion of Jeffrey Kappel and S. Brett Luz to key financial positions effective August 30. Kappel has been appointed senior VP and CFO and Luz has been named VP and Chief Accounting Officer. Both of these positions were previously held by Van Welch, who has tendered his resignation effective August 30.

17:02 EDT Belmond backs FY17 same store hotel RevPAR growth view 2%-6% in USD

17:01 EDT ArcLight Capital to enter joint venture with BP West Coast Products - ArcLight Capital Partners announced that one of its affiliates signed definitive agreements with BP West Coast Products, as a result of which they will enter into a joint venture across refined product logistics infrastructure assets in the US Pacific Northwest. The JV will be anchored initially by the acquisition of two large-scale refined product terminals in Seattle, Washington and Portland, Oregon. The transaction is expected to close in late 2017, subject to customary approvals. TLP Management Services, an ArcLight affiliate, will operate the terminals under a multi-year operating agreement. Separately, ArcLight intends to grant TransMontaigne Partners, also an ArcLight affiliate, a right of first offer to purchase ArcLight's interest in the JV.

16:59 EDT Halis Family Foundation reports 5.1% passive stake in Pendrell

16:55 EDT FedEx says addressing some functionality issues - In a tweet, the company said: "We are addressing some functionality issues and are working to resolve as soon as possible. We sincerely regret any inconvenience." Reference Link

16:54 EDT Marriott added roughly 16,000 rooms during Q2 - Including nearly 2,300 rooms converted from competitor brands and more than 5,900 rooms in international markets. At quarter-end, Marriott's worldwide development pipeline increased to more than 440,000 rooms, including roughly 42,000 rooms approved, but not yet subject to signed contracts.

16:53 EDT Ackman's Pershing reports 8.3% stake in ADP - Bill Ackman's Pershing Square Capital Management disclosed an 8.3% stake in ADP. Pershing said it has engaged in and intends to continue to engage in discussions with the company's management and board, other stockholders and other interested parties that may relate to the governance and board composition, business, operations, cost structure, management, assets, capitalization, financial condition, strategic plans, and the future of ADP. Initial discussions with the company to extend its August 10 director nominations deadline have not resulted in an extension. Pershing wrote in a regulatory filing which allows for activism. As a result Pershing is submitting a stockholder proposal and director nomination notice to ADP. The fund earlier announced in a press release the nomination of three board members, one of which is Bill Ackman.

16:50 EDT Digital Turbine sees Q2 revenue $27M, consensus $26.77M - Expects further sequential improvement in non-GAAP adjusted EBITDA during Q2. The Company expects to generate positive non-GAAP adjusted EBITDA for the FY18.

16:48 EDT Pershing Square reports 8.3% stake in ADP

16:45 EDT Allegiant Travel reaffirms Q3 TRASM guidance (0.5)%-1.5%

16:44 EDT Allegiant Travel reports July total system passengers up 7.1% - Reports July revenue passenger miles up 3.1% and available seat miles 3.0%.

16:42 EDT Thermo Fisher subsidiary extends offering period for tender offer for Patheon - Thermo Fisher Scientific (TMO) announced that its wholly owned subsidiary, Thermo Fisher Luxembourg has extended the offering period of its previously announced all-cash tender offer to purchase all of the outstanding ordinary shares of Patheon (PTHN). The tender offer is being extended to coordinate with the timing of the two remaining regulatory approvals in the European Union and Brazil. The company's anti-trust filing was submitted to the European Union on July 19, 2017, initiating the 25 business-day review period. In Brazil, competition authorities approved the transaction today, initiating a 15 calendar-day comment period. Thermo Fisher previously received clearances from regulatory authorities in the U.S. and Canada. Based on progress to date, Thermo Fisher now expects to complete the transaction around the end of Q3.

16:41 EDT La Quinta backs prior FY17 EBITDA view of $320M-$340M - Based upon management's current estimates, the company is reaffirming its guidance for the full year 2017 of RevPAR growth on a system-wide comparable hotel basis 0.0 percent to 2.0 percent Adjusted EBITDA $320 million to $340 million

16:35 EDT Black Stone Minerals raises FY17 average daily production view to 37-38 MBoe/d - Previous view 35-37 MBoe/d.

16:32 EDT Endo reaches agreements to resolve all known U.S. mesh product liability claims - Endo announced that it has reached agreements to resolve virtually all known U.S. mesh product liability claims and that it is engaged in discussions to resolve the known remaining U.S. claims at reasonable values. Under the agreements, Endo will make installment payments beginning in the fourth quarter of 2017 and continuing through the fourth quarter of 2019. As part of its second quarter 2017 results, the Company intends to increase its mesh product liability accrual by $775M, which is expected to cover approximately 22,000 U.S. mesh claims, as well as all known international mesh product liability claims and other mesh-related matters. While Endo cannot predict the resolution of any unresolved claims or the number of any future claims, as of the date of this announcement, Endo is unaware of any mesh-related matters not covered by the foregoing accrual increase. "Beginning in the second quarter of 2017, we aggressively executed a settlement strategy in connection with Endo's mesh litigation. We believe it is a very important milestone for Endo to have reached agreements to resolve virtually all known U.S. mesh product liability claims," said Paul Campanelli, Endo's President and CEO. "While it remains possible that additional claims will be filed, we believe today's announcement will assist most mesh claimants to move forward with their lives and will permit Endo to move forward with an even greater focus on executing against our core strategic priorities," he added.

16:30 EDT Nexstar to acquire non-spectrum assets of WLWC-TV for $4.1M - Nextar Media announced that its subsidiary, Nexstar Broadcasting, Inc., has entered into a definitive agreement to acquire the non-spectrum operating assets of WLWC-TV, the CW affiliate serving Providence, RI for $4.1M from OTA Broadcasting, LLC. The transaction will be highly accretive to Nexstar's operating results immediately upon closing, which is expected by early fourth quarter of 2017. Nexstar intends to finance the station acquisition with cash from operations.

16:28 EDT Marriott sees FY17 investment spending about $500M-$700M - The company expects investment spending in 2017 will total approximately $500 million to $700 million, including approximately $175 million for maintenance capital. Investment spending also includes other capital expenditures (including property acquisitions), new mezzanine financing and mortgage notes, contract acquisition costs, and equity and other investments. Assuming this level of investment spending and no additional asset sales, roughly $2.5 billion could be returned to shareholders through share repurchases and dividends in 2017.

16:28 EDT Invitae reports cash and equivalents $80.4M at June 30

16:26 EDT Marriott sees Q4 comparable systemwide RevPAR up 1%-3% in North America - For the 2017 fourth quarter, Marriott expects comparable systemwide RevPAR on a constant dollar basis for the combined company will increase 1 to 3 percent in North America, 2 to 4 percent outside North America and 1 to 3 percent worldwide. The company assumes fourth quarter total fee revenue will total $804 million to $849 million. These fee revenue estimates reflect about $5 million of unfavorable foreign exchange. Marriott expects fourth quarter 2017 owned, leased, and other revenue, net of direct expenses, could total approximately $97 million. This estimate reflects the negative impact of hotels previously sold.

16:25 EDT Marriott sees Q3 comparable systemwide RevPAR roughly flat in North America - For the 2017 third quarter, Marriott expects comparable systemwide RevPAR on a constant dollar basis for the combined company will be roughly flat in North America. The company's guidance for third quarter RevPAR growth in North America reflects the shift of the Jewish holidays, which fall in the third quarter of 2017 compared to the fourth quarter of 2016, as well as the Fourth of July shift to mid-week year-over-year. The company expects third quarter comparable systemwide RevPAR on a constant dollar basis for the combined company will increase 3 to 5 percent outside North America and 1 to 2 percent worldwide. The company assumes third quarter total fee revenue will total $810 million to $825 million. These fee revenue estimates reflect about $5 million of unfavorable foreign exchange. Marriott expects third quarter 2017 owned, leased, and other revenue, net of direct expenses, could total approximately $75 million. This estimate reflects the negative impact of hotels previously sold. The company expects that owned, leased results in the third quarter will be constrained by tough comparisons to the 2016 Olympics. Marriott expects third quarter 2017 adjusted EBITDA could total $770 million to $790 million, reflecting tough comparisons caused by the Olympics and the shift in the Jewish holidays year-over-year. This estimate reflects the negative impact of hotels previously sold. See page A-13 for the adjusted EBITDA calculation.

16:22 EDT Envision Healthcare says on track to capture expected financial synergies - The company said, "Our operating and financial performance confirms our strategic rationale for the transformational merger that we completed eight months ago. We are on track to capture the expected financial synergies, continue to generate interest among health systems for our solutions, and have expanded our platform with the acquisition of nine physician group practices and four ambulatory surgery centers (ASCs) during the first half of 2017. At the same time, we are successfully streamlining our operations and focusing on our core physician-centric activities Envision reports two operating segments as continuing operations: Physician Services, which includes facility-based and post-acute services; and Ambulatory Services. This follows the decision earlier this year to market and divest American Medical Response, Envision's Medical Transportation business. As a result of the movement of this business to discontinued operations, and as required by accounting guidelines, Envision re-allocated certain corporate expenses associated with its shared services model to continuing operations. This re-allocation impacts segment Adjusted EBITDA by $8.5 million for the three months ended June 30, 2017. The re-allocation results in a reduction of Adjusted EBITDA in the second quarter of $6.5 million for Physician Services and $2.0 million for Ambulatory Services, with a corresponding Adjusted EBITDA increase of $8.5 million for discontinued operations. Upon the planned divestiture of the Medical Transportation business, a portion of these shared services are likely to remain with that business."

16:21 EDT Valeant receives CRL on NDA for latanoprostene bunod ophthalmic solution - Valeant announced it has received a Complete Response Letter from the U.S. FDA regarding the New Drug Application for latanoprostene bunod ophthalmic solution, 0.024%, an investigative intraocular pressure lowering single-agent eye drop for patients with open angle glaucoma or ocular hypertension. The CRL from the FDA only refers to a Current Good Manufacturing Practice inspection at Bausch + Lomb's manufacturing facility in Tampa, Fla. The FDA did not identify any efficacy or safety concerns with respect to the NDA or additional clinical trials needed for the approval of the NDA for latanoprostene bunod ophthalmic solution, 0.024%. Valeant will work closely with the FDA to determine the appropriate next steps for the NDA.

16:17 EDT Fiesta reports July SSS down 6.4% at Pollo Tropical, 8.9% at Taco Cabana - Fiesta Restaurant Group reports July comparable restaurant sales decreased 6.4% at Pollo Tropical and decreased 8.9% at Taco Cabana. "After suspending broadcast media during the second quarter at both brands, media was reintroduced starting in late June in some Pollo Tropical markets," the company said.

16:16 EDT TPI Composites appoints Joseph Kishkill as Chief Commercial Officer - TPI Composites announced that it has hired Joseph Kishkill as its Chief Commercial Officer, effective August 21. In this position, Joe will lead TPI's diversified growth strategy, including all commercial aspects of the wind blade business and TPI's diversified markets effort.

16:13 EDT ViewRay reaffirms FY17 revenue view $45M-$50M, consensus $48.18M - Source of revenue is primarily from the sale of 7 to 8 MRIdian Linac Systems.

16:10 EDT Plains All American sees FY18 adjusted EBITDA $2.45B-$2.65B

16:09 EDT AppFolio appoints Jason Randall CEO - AppFolio announced that Jason Randall will succeed Brian Donahoo as president and CEO following Donahoo's retirement, effective August 8. Donahoo will also be stepping down from his role as a director on the same date, and the board has elected Randall to serve in his place. Donahoo will continue to serve as an employee through December 31 to assist in the orderly transition of his roles and responsibilities.

16:09 EDT CBS reports Q2 Publishing revenues of $206M, up 10% - Publishing revenues of $206 million for the second quarter of 2017 grew 10% from $187 million for the same prior-year period. The increase was led by growth in print book sales and digital audio sales. Bestselling titles for the second quarter of 2017 included Lord of Shadows by Cassandra Clare and I Can't Make This Up by Kevin Hart. Publishing operating income of $28 million for the second quarter of 2017 increased 8% from $26 million for the same prior-year period, mainly reflecting the revenue growth.

16:08 EDT CBS reports Q2 Entertainment revenue up 12% to $2.18B - Entertainment revenues of $2.18 billion for the second quarter of 2017 were up 12% from $1.95 billion for the same prior-year period. This increase was led by 38% growth in affiliate and subscription fees, driven by higher station affiliation fees and subscriber growth at CBS All Access. Advertising revenues increased 6%, as a result of the broadcast of the semifinals and finals of the NCAA Tournament on the CBS Television Network. Content licensing and distribution revenues benefited from more television licensing activity in the second quarter of 2017 and grew 12%, despite the difficult comparison with the prior-year period, which included the international licensing sales of five Star Trek series. Entertainment operating income of $346 million for the second quarter of 2017 decreased 1% from $351 million for the same prior-year period, primarily reflecting higher-margin revenues in the second quarter of 2016.

16:08 EDT Sunrun sees Q3 deploment of approximately 88 MW - The following statements are based on current expectations. These statements are forward-looking and actual results may differ materially. In Q3, Sunrun expects to deploy approximately 88 MW, reflecting 15% growth for the first three quarters of 2017 compared to the prior year. For the full year 2017, Sunrun continues to expect to deploy 325 MWs, reflecting 15% year-over-year growth.

16:07 EDT Xencor expects to end FY17 with $340M in cash and equivalents - Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations beyond 2020. Xencor expects to end 2017 with approximately $340M in cash, cash equivalents and marketable securities.

16:04 EDT Hawaiian Airlines reports July traffic up 1.9% - Hawaiian Airlines, a subsidiary of Hawaiian Holdings, announced its system-wide traffic statistics for the month of July, reporting passengers were up 2.5% compared to the same month of last year, traffic as measured by RPMs was up 1.9% and capacity as measured by ASMs was up 0.5%. Load factor was 87.3% in July, compared to 86.2% in the same month of 2016.

16:03 EDT Mistras appoints Dennis Bertolotti CEO - Mistras Group announced that its board appointed Dennis Bertolotti as its president and CEO, effective August 10, succeeding Mistras's founder and chairman, Dr. Sotirios Vahaviolos. Vahaviolos will remain active in the business as executive chairman, focusing on strategy and technology, and will continue to lead the board. Bertolotti has also been elected to serve on the Mistras board commencing August 10.

15:38 EDT Forest Manor raises passive stake in USA Technologies to 6.15%

13:35 EDT Inpixon announces two delivery orders from Bureau of Census - Inpixon announced that subsidiary, Inpixon Federal, received two delivery orders from the Bureau of Census, based on Inpixon Federal's GSA IT 70 Schedule, for a one year software Enterprise License Agreement and 24x7 maintenance. The value of the orders is over $1.4M, the company stated.

13:15 EDT CSRA awarded $59M task order from NAVSEA - The Naval Sea Systems Command has awarded CSRA a $59M task order in support of its Research and Systems Engineering Directorate. The Task Order has a one-year base period and four one-year options. The $59M task order will allow CSRA to continue providing Engineering Support Services for NAVSEA's mission of designing, building, delivering, and maintaining the Navy's ships, including: amphibious, auxiliary, and fleet support ships and systems.

12:49 EDT Hyatt announces plans for two Hyatt Centric hotels in Peru, Chile - Hyatt Hotels announced that a Hyatt affiliate has entered into a franchise agreement with Talbot Hotels S.A. for two Hyatt Centric hotels in Lima, Peru and Santiago, Chile. Expected to open in early 2018, the two hotels will mark the introduction of the Hyatt Centric brand to Peru and Chile.

12:48 EDT Cooperman says looking for better entry point into bank stocks - Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Leon Cooperman of Omega Advisors is speaking on CNBC.

12:44 EDT Monsanto, Valent U.S.A. announce expanded partnership in Roundup Ready PLUS - Monsanto and Valent U.S.A. LLC, a wholly-owned subsidiary of Sumitomo Chemical Company, announced their expanded partnership in the 2018 Roundup Ready PLUS Crop Management Solutions platform. Several key changes provide soybean, corn and cotton growers with the most effective solutions to be more productive. Valent will offer Valor and Fierce brands as the exclusive preemergence PPO residual herbicides in the program. In addition, new products will be added to the program, including solutions for control of tough weeds, such as new Mauler Herbicide and a line extension of the longest lasting residual, Fierce, with Fierce MTZ Co-Pack. Valor SX Herbicide will again be part of the program for 2018. Rowel Herbicide and Rowel FX Herbicide will be phased out to streamline product offerings. Valent's line of postemergence herbicides, including Cobra and Select Max Herbicide with Inside Technology, will remain in the program. In addition, growers will have access to the latest insecticide solutions from Valent in the 2018 program. Asana XL Insecticide, an industry leader for broad spectrum foliar insect control and Zeal SC, a proven residual miticide, will both be offered in the 2018 program. Valent and Monsanto are pleased to offer a broader range of insecticide solutions that will help growers maximize yields and protect their acres throughout the growing season.

12:34 EDT Cooperman names Nabors, Hess, WPX, Keane Group as oil picks - Leon Cooperman of Omega Advisors is speaking on CNBC.

12:26 EDT Cooperman says market fully valued, but not seeing 'euphoria' - Leon Cooperman of Omega Advisors is speaking on CNBC.

12:12 EDT Cooperman says Ackman 'dead wrong' on ADP - Leon Cooperman of Omega Advisors is speaking on CNBC.

12:09 EDT NJ posts notice regarding 58 planned layoffs at Bristol-Myers - Bristol-Myers Squibb (BMY) gave notice of planned layoffs related to 58 employees working at its location in Lawrence Township, according to a W.A.R.N. notice issued in New Jersey. A similar "Worker Adjustment and Retraining Notification Act" notice issued by the state was at the center of some confusion regarding employee plans at Blue Apron (APRN) on Friday, The Fly notes.

12:02 EDT Cooperman calls ADP 'unbelievable success story' - Leon Cooperman of Omega Advisors is speaking on CNBC.

11:57 EDT Time Inc. names Katie J. Stanton to board - Time Inc. (TIME) announced the appointment of Katie J. Stanton, Chief Marketing Officer of Color, a health technology service that offers physician-ordered genetic testing for hereditary cancer risk, and former VP, Global Media at Twitter (TWTR), to its board of directors. Stanton will serve on the Compensation Committee of the board.

11:48 EDT Investors seen with 'upper hand' as Elliott fights for higher NXP takeout price - Morgan Stanley analyst Craig Hettenbach believes NXP Semiconductors (NXPI) shareholders "have the upper hand" in seeking to push for a higher takeout price from Qualcomm (QCOM), which could be a win/win for all parties involved as a higher bid would be inconsequential to Qualcomm's balance sheet and deal accretion math. HIGHER TAKEOUT PRICE: Activist investor Elliott Management disclosed a 6% stake in the latter on Friday, with reports indicating that the firm is pushing to see Qualcomm increase its agreed upon buyout price of $110 per NXP share. In a research note to investors this morning, Morgan Stanley's Hettenbach argued that he believes NXP Semiconductors' shareholders "have the upper hand" for attempting to drive a higher takeout price. A higher bid would be "inconsequential" to the balance sheet and deal accretion calculus of Qualcomm, which needs the support of 80% of NXP Semiconductors' shareholder for the tender approval, Hettenback pointed out. Hettenbach added that his discussions with many of NXP Semiconductors' shareholders suggest they would not tender shares at $110. Nonetheless, if Qualcomm needs to increase its offer to $120 per share to achieve that, the analyst noted he does not believe it would have a meaningful impact on its balance sheet or the deal accretion math. The analyst, who sees momentum building for a higher deal price and has a "hard time believing" Qualcomm would walk away rather than raise the price and get a deal done, raised his price target on NXP to $117.50 from $110. He reiterated an Equal Weight rating on NXP Semiconductors' shares. WHAT'S NOTABLE: On Friday, Bloomberg reported that Paul Singer's Elliott Associates wants NXP Semiconductors to renegotiate with Qualcomm, find a higher bid elsewhere or remain a standalone company. The activist fund believes all three options offer better value than Qualcomm's current takeover offer, a source told Bloomberg. PRICE ACTION: In late morning trading, shares of NXP Semiconductors are fractionally up to $112.89. Over the last month, the stock has risen about 3.5%.

11:32 EDT Moody's assigned B2 Corporate Family Rating to Tesla - Moody's assigned a B2 Corporate Family Rating to Tesla and a B3 rating to the company's offering of senior unsecured notes. The company's Speculative Grade Liquidity is SGL-3, and the rating outlook is stable. "The B2 CFR reflects Moody's expectation that the launch, production ramp up, and market acceptance of the Model 3 will be successful enough to achieve approximately 300,000 unit sales during 2018 (a full-year sales rate averaging about 5,500 per week) with a gross margin approximating 25%. This level of sales and profitability would enable Tesla to strengthen its performance from sizable losses to an operating position that supports the B2 CFR," the ratings agency said in a statement. It added, "The B3 rating of the unsecured notes reflects the junior position of the notes relative to the company's $1.9 billion secured credit facility. The stable outlook reflects Moody's expectations that the shipment levels and profitability of the Model 3, combined with an adequate liquidity profile, will enable the company to materially strengthen its operating performance and credit metrics during 2018."

11:30 EDT Acorda Therapeutics: Initiating sale process would 'destabilize operations' - In a regulatory filing, Acorda Therapeutics issued a statement in response to the letter filed today by Scopia Capital Management: "The Acorda Board of Directors and management team are committed to acting in the best interests of shareholders and all Acorda stakeholders. As part of its contingency planning related to the AMPYRA patents, Acorda's Board and management team thoroughly considered options to enhance shareholder value, as they do regularly. Based on this recent review, the Board unanimously determined that focusing on our two late-stage programs in Parkinson's disease (INBRIJA and tozadenant) and maximizing AMPYRA is the best path forward to create value for shareholders. We believe that a sale of the Company at the present time would not adequately compensate shareholders for the potential benefits of the Company's late-stage programs. Moreover, initiating a sale process or a public review of strategic alternatives at this point would destabilize operations, hinder our ability to execute on the Company's business plan and risk significantly devaluing the Company. Acorda welcomes open communications with all shareholders and values their constructive input. In this regard, members of our senior management team have held numerous meetings with Scopia over the past two years, and in particular over the last several months, and certain Board members have also met with them. We have fully considered Scopia's proposals. Our Board understands, and is committed to, its fiduciary duties to act in the best interests of shareholders, as well as its responsibilities to all of its stakeholders, including the many patients with debilitating neurological disorders who are served by the Company's innovations, commitment and expertise. Acorda's management team and Board are implementing the Company's plan focused on value creation, and maintaining the financial position of the Company to enable investment into our development of medicines."

11:17 EDT RPX Corp. names President and CEO Marty Roberts to board - RPX Corporation announced that its CEO and President, Marty Roberts, has been appointed to the company's board, effective August 3. With this appointment, the RPX Board expands to nine members, including seven independent directors. Roberts has served as RPX's CEO since February 5.

10:30 EDT Rockwell Collins rallies with United Technologies seen considering pursuit - Shares of Rockwell Collins (COL) rallied in morning trading following reports that said United Technologies (UTX) is weighing a bid for the aircraft component maker. Analysts were mixed on a potential deal, with one analyst calling the deal timing "surprising" and stating he is "skeptical" of a deal and another noting that a deal could strengthen the Dow member. POTENTIAL BID: United Technologies is weighing a bid for Rockwell Collins, according to reports on Friday from Bloomberg and Reuters. According to Bloomberg, people familiar with the matter said it is not clear whether the two companies are currently in talks and whether the deliberations will lead to a deal. Rockwell Collins, which closed the acquisition of B/E Aerospace in April, has a market value of $19.3B, suggesting a potential deal would exceed United Technologies' 2012 purchase of Goodrich Corp for $18B. According to Reuters, Rockwell Collins is working with an investment bank to review United Tech's offer. United Technologies and Rockwell Collins have not commented on the reports. WHAT'S NOTABLE: A deal with United Technologies would open the way for Rockwell to capitalize on "connected aircraft" that can transmit data about onboard systems, routes and weather, allowing airlines to improve operations and maintenance, Reuters said. United Tech's Pratt & Whitney unit has faced production problems with some of its Geared Turbofan engines that caused Airbus (EADSY) to delay deliveries of the A320neo aircraft and the company has noted "challenges" in the China market. In 2016, United pulled out of talks related to a potential takeover by Honeywell (HON). "MIXED EVENT" FOR UNITED: In a note to clients, Wells Fargo analyst Sam Pearlstein said that while United has "long expressed interest" in adding avionics, the timing of its interest in Rockwell Collins is "surprising," partly because major airplane makers, including Boeing (BA), are considering moving into avionics and aftermarket as well. Pearlstein said he is "skeptical" that a deal is imminent, but if a transaction were to occur, he estimated that United would pay about $150 per share for Rockwell. Pearlstein has an Outperform rating on both stocks. Separately, JPMorgan analyst C. Stephen Tusa said that, at face value, an acquisition of Rockwell Collins would be a "mixed event" for United Technologies. While benefits would include a "solid" strategic rationale that plays into the broader aerospace sector narrative and some earnings accretion, the potential size of the acquisition dilutes the positives "somewhat" and would make achieving targeted returns a "challenge." Tusa also noted that a stock issuance could be required for United Technologies. RBC Capital analyst Matthew McConnell was more upbeat on a potential deal, telling clients that a deal has "ample strategic rationale" and would strengthen United Technologies, but noted that airplane makers have expressed opposition to similar deals in the past. McConnell, who raised his price target on Rockwell Collins to $133 from $120, thinks that there is a 50% chance of a deal taking place and believes Rockwell could be bought for $145 per share. PRICE ACTION: Shares of Rockwell Collins are up about 4% in morning trading to $123.43. Meanwhile, United Technologies is down 2% to $118.88.

10:28 EDT Kanen Wealth raises stake in New York & Co. to 6.3% from 5.1% - Kanen Welath said in the current filing that, "Kanen Wealth has engaged in and may to continue to engage in discussions with the board and management of New York & Co regarding its business and affairs. Kanen Wealth reserves the right in the future to formulate any such plans or proposals, and to take any actions with respect to their investments in New York & Co." In early May, Kanen Wealth made the following statement in response to comments from New York & Co: "Dear NWY Management & Board of Directors: We are deeply disappointed with your shallow and superficial response to our recent letter and 13-D filing. What's disappointing is your clear expression that the current plan, path, and trajectory is sufficient. You state that you merely need to add a board member "with expertise in new or growing areas of our business, such as E-Commerce, Omni-Channel or Digital, in order to provide a unique and fresh perspective". Perhaps more talent in the "new or growing areas of our business" would be beneficial, but what's alarming is you seem to be oblivious to the most important point and fact that I have been trying to make. It is the reason you have a losing record and a stock price that has declined more than 75% in approximately 4 years."

10:17 EDT Snap shares seen poised for second half rebound - Deutsche Bank analyst Lloyd Walmsley told investors in a research note this morning that he believes Snap's (SNAP) shares should rebound as second half of the year inflection comes into focus and as continued product innovation drives Daily Active User, or DAU, and engagement growth over time. REBOUND AHEAD: Deutsche Bank's Walmsley told investors in a research note that he has always modeled Snap as a "big" second half of the year story, and his upbeat ad checks suggest a big revenue ramp remains on track. The analyst also pointed out that he disagrees with the narrative that the company is not innovating. Walmsley noted that he sees innovation thriving at Snap across the app, ad product, and ad tech, and continued product innovation should drive DAU and engagement growth over time. Further, the analyst said his intra quarter ad checks have started to pick up with industry contacts noting brand advertisers measuring ROIs are increasingly of the view that Snap offers compelling view rates, view-to-completion rates, and ROIs. Snap is moving quickly to improve ad tech product to address more budget, he contended, adding that while work needs to be done, investors are "overly negative" on the progress at Snap relative to his industry conversations. Walmsley argued that Snap shares offer a "compelling" risk/reward profile at current levels, and would take advantage of lockup supply to add to long-term positions. The analyst reiterated a Buy rating and a $20 price target on the shares. WHAT'S NOTABLE: Snap was in the spotlight last week after three sources told Business Insider that they had "heard the chatter" that Google (GOOG; GOOGL) made an offer to acquire the social media company in early 2016. According to the publication, the Alphabet unit is rumored to have bid "at least" $30B, which is about double the company's market cap now that it is public, to buy Snap. PRICE ACTION: In morning trading, shares of Snapchat's parent have gained over 3% to $13.97. After pricing its IPO at $17 per share on March 2, Snap finished its first day of trading with an advance of about 44%, closing at $24.51 per share.

10:01 EDT Comtech receives $3.7M order from mobile network operator - Comtech announced that during its fourth quarter of fiscal 2017, its Enterprise Technologies group, which is part of Comtech's Commercial Solutions segment, received a $3.7M order from a major U.S. mobile network operator for its advanced location platform supporting the customer's 4G/LTE network. The order is part of a multi-year development, deployment and support contract valued at more than $7M.

10:00 EDT BorgWarner sees revenue growing to $11.5B by 2020 - The growth from 2016 revenue of $8.8B represents a CAGR of 7%, according to the company's investor day presentation. Sees operating margin growing to "low 13% range" by 2020 from the proforma level of 12.6% in 2016. BorgWarner sees capital spending to be 5.5%-6.5% of sales, with 80% for growth programs, 4% of revenue spent on R&D and dividend growth "in line with cash flow" and "adequate liquidity" maintained for M&A. The company added: "New 2020 outlook indicates BorgWarner is tracking ahead of our 2023 goals." Guidance and comments from investor day presentation slides.

09:43 EDT CVI Investments reports 8.3% passive stake in Neuralstem

09:39 EDT Tyson Foods says to provide AdvancePierre integration update by early 2018

09:31 EDT CBS reaches agreement with AT&T to join 'DirecTV Now' live TV service - AT&T (T) and CBS Corporation (CBS) announced a new agreement to carry CBS, as well as SHOWTIME, The CW, Pop and CBS Sports Network, on AT&T's DIRECTV NOW live TV streaming service. All networks in the deal will be available to stream live, with much of their programming available on demand as well. Financial terms of the agreement were not disclosed. DIRECTV NOW will feature live streaming of CBS-owned local television stations in many of the largest U.S. markets at launch. All affiliates of CBS and The CW will have the opportunity to participate going forward as well.

09:25 EDT Tyson Foods sees FY18 CapEx increasing from FY17 - Tyson CEO Tom Hayes says the company has seen tremendous demand for bacon in food service. Hayes says the company is expanding antibiotic-free chicken to food service. Hayes says Tyson is focused on fresh meal kits, breakfast and nine core brands. The executive also says that automation is more important in the "tightening" labor market. Expects AdvancePierre to be accretive "in upper teens" in FY18. Sees FY18 CapEx increasing from FY17.

09:22 EDT Coherus Biosciences files petition for Inter Partes Review in UTSPO - Coherus BioSciences announced that it has filed a petition for Inter Partes Review in the U.S. Patent and Trademark Office, or UTSPO, seeking invalidation of U.S. Patent 8,163,522. The '522 patent, controlled by Amgen, is generally directed to a method for making etanercept, the pharmaceutically active component of ENBREL. Coherus also announced its intention to file an IPR in the near future seeking invalidation of related U.S. Patent 8,063,182, also controlled by Amgen and generally directed to the etanercept protein.

09:20 EDT ITUS and The Wistar Institute renew collaboration for development of Cchek - ITUS announced that ITUS and The Wistar Institute have renewed their collaboration for the development of Cchek, the company's early cancer detection technology.

09:19 EDT Ferrellgas Partners LP acquires two Tennessee propane retailers - Ferrellgas Partners announced the acquisition of two Tennessee propane retailers, Lindsey Propane and Sevier County Propane. The transaction is expected to be immediately accretive and will allow Ferrellgas to better service customers in central and eastern Tennessee regions. Terms of the transaction were not disclosed. A local provider in Williamsport, Tennessee, Lindsey Propane offers commercial, industrial, agricultural, and residential propane services to customers in nine middle Tennessee counties.

09:16 EDT Terreno Realty acquires building in Miami for $2.5M - Terreno Realty acquired an industrial property located in Miami, Florida on August 4, 2017 for a purchase price of approximately $2.5M. The property consists of one industrial distribution building containing approximately 16,000 square feet on 0.6 acres at 2000 NW 70th Avenue immediately adjacent to Miami International Airport and three existing Terreno Realty Corporation properties on NW 70th Avenue. The property provides four dock-high loading positions, parking for 17 cars and is 100% leased to one tenant on a short-term basis. The estimated stabilized cap rate of the property is 6.1%.

09:09 EDT FX Networks, Comcast partner for new commercial-free television service - Comcast (CMCSA, CMCSK) and FX Networks (FOX, FOXA) will launch FX+, a new service that will allow Xfinity TV subscribers to upgrade to a platform featuring commercial-free current seasons of every FX and FXX original series and every season of many current and legacy library titles of FX originals, it was announced by John Landgraf, CEO, FX Networks and FX Productions and Matt Strauss, Executive Vice President and General Manager, Video and Entertainment Services, Comcast Cable. FX+ will launch on September 5th and Xfinity TV customers can add the new service to their video package for $5.99 per month. In addition to offering complete in-season stacking rights to all of its current original series commercial free, FX Networks is now the first ad-supported cable portfolio to offer all seasons of the majority of its original series library. Due to the number of episodes in the FX Networks library, the shows will be rolled out over a period of time and it is expected that the complete FX+ roster will be available in 2018. FX+ subscribers will be able to access the FX+ content via Xfinity On Demand, the Xfinity Stream app and website, and FXNOW. In the future, FX+ will also offer select series in 4K as well as temporary downloads of current season episodes.

09:06 EDT Cinedigm's Dove Channel launches in Canada - Cinedigm (CIDM) announces that Dove Channel, one of its digital streaming subscription services, is now available in Canada. The channel offers both ad-supported and commercial-free subscription programming, and can be viewed initially on Android and Apple's (AAPL) iOS devices, with a broad spectrum of connected devices including Roku Players and Roku TV models, Amazon (AMZN) Fire, tvOS, and all major web browsers to follow. Dove Channel, launched in the U.S. on September 15, caters to families seeking quality, safe, family-friendly content.

09:04 EDT Jaguar Animal Health announces oprhan-drug designation for Napo's Mytesi - Jaguar Health announced that Mytesi, a product of Jaguar's wholly-owned subsidiary Napo Pharmaceuticals, has received orphan-drug designation from the U.S. Food and Drug Administration for the treatment of short bowel syndrome. Mytesi is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Orphan Drug Act provides for granting special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor. In countries such as the United Arab Emirates and Saudi Arabia, SBS occurs with much higher incidence, and Napo has visited with medical centers in this region.

09:03 EDT Kadmon says FDA grants orphan drug designation for tesevatinib - Kadmon Holdings announced that the U.S. FDA has granted orphan drug designation to tesevatinib, the company's oral tyrosine kinase inhibitor, for the treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations. This is the second orphan drug designation for tesevatinib; the first designation was granted in March 2016 for the treatment of autosomal recessive polycystic kidney disease. Kadmon is conducting ongoing Phase 2 clinical trials of tesevatinib for the treatment of EGFR-mutation-positive NSCLC that has metastasized to the brain and/or the leptomeninges and for the treatment of glioblastoma. The company is also developing tesevatinib for the treatment of autosomal dominant polycystic kidney disease and ARPKD and expects to initiate clinical trials in these indications in Q3.

09:02 EDT Regions Financial sees adjusted EPS CAGR of 12%-15% from 2016-2018 - From 2016-2018, Regions sees an adjusted EPS compound annual growth rate of 12%-15%, an adjusted efficiency ratio below 60% and adjusted ROATCE of 12%-14%. The long-term expected results are outlined in slides posted to its investor relations website.

09:01 EDT MSC Industrial acquires Deco Tool Suply - MSC Industrial has acquired DECO Tool Supply, an industrial supply distributor based in Davenport, Iowa. The transaction was completed on July 31. DECO's annual revenue was approximately $100M in 2016, generated by 190-plus associates across 10 branch offices located primarily in the Midwest. DECO's sales force and branch footprint complements MSC's coverage in the region. In time, MSC will be able to provide DECO customers access to MSC's one million-plus product portfolio to support their full metalworking and MRO needs.

09:01 EDT Office Depot announces same-day delivery coming to Atlanta, LA - Office Depot announced same-day delivery powered by Deliv-- a crowdsourced, last-mile logistics company providing same-day delivery and returns for omnichannel retailers, local businesses and e-commerce companies--is launching on August 28 in Atlanta, Georgia and Los Angeles, California; and on September 6 in Ft. Lauderdale/Miami, Florida. The same-day delivery service is designed to better meet customer expectations as the omnichannel shopping experience continues to expand.

08:51 EDT Zynerba plunges after ZYN002 doesn't show significant seizure reduction - Shares of Zynerba Pharmaceuticals are plunging after the company announced that ZYN002 did not demonstrate a statistically significant reduction of focal seizures during the treatment period compared to the baseline period for either the high or low dose cohorts compared to placebo in the company's Phase 2 STAR 1 clinical trial. In a prior research note to investors, Jefferies analyst Biren Amin pointed out that the STAR-1 trial represents a "critical catalyst" for Zynerba as it provides the first proof of concept for transdermally delivered CBD. At the time his note was published in early July, Amin predicted that a lack of treatment effect could drop shares to $4-$5. In pre-market trading, Zynerba shares are down $8.21, or 54.5%, to $6.85.

08:47 EDT Core Molding initiates quarterly dividend of 5c per share - Core Molding announced that its board of directors has authorized the payment of a quarterly cash dividend, the first in the company's history. "The announcement highlights the company's confidence in its operational performance, expected growth and long-term strategy," the company said. Core Molding is initiating a regular quarterly cash dividend of 5c per share. The first quarterly dividend will be payable on August 30 to all common shareholders of record as of August 18. The dividend initiation does not diminish the company's ability to deploy capital for organic growth opportunities or potential acquisitions.

08:36 EDT Finjan Holdings sues SonicWall for patent infringement - Finjan Holdings announced that its subsidiary Finjan, Inc. has filed a patent infringement lawsuit against SonicWall, Inc., a Delaware Corporation, in the Northern District of California alleging infringement of ten of Finjan U.S. patents. Finjan initially engaged with SonicWall in June of 2014 to introduce Finjan's patents in the cybersecurity space, the claimed technology of which is directed to behavior-based technologies to disable malicious content. Finjan sought to extend a license to its patent portfolio to SonicWall for fair value at that time. After more than 36 months of protracted negotiations, Finjan was compelled to protect the value of its established patent portfolio by filing this suit. Finjan always prefers a path to granting a fair valued license that does not require litigation but has had to turn to the courts on a number of occasions to seek resolution. Finjan filed a Complaint on August 4, 2017, in the U.S. District Court for the Northern District of California, alleging that numerous SonicWall products and services infringe ten U.S. Finjan patents. Finjan is asserting infringement of U.S. Patent Nos. 6,154,844; 6,804,780; 6,965,968; 7,058,822; 7,613,926; 7,647,633; 7,975,305; 8,141,154; 8,225,408; 8,677,494. In the action, Finjan is seeking, among other things, a preliminary and permanent injunction, an award to Finjan of damages, determination that infringement has been willful and deliberate and reasonable attorneys' fees and costs.

08:32 EDT Kite Pharma initiates axicabtagene ciloleucel CAR-T clinical program in the EU - Kite Pharma announced that patients in the European Union are now being treated with its lead investigational candidate, axicabtagene ciloleucel, in the safety expansion cohort of ZUMA-1. Kite is currently enrolling adult patients with relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma at multiple EU medical centers. Kite filed a Marketing Authorization Application to the European Medicines Agency for axicabtagene ciloleucel in July 2017, the first CAR-T application in Europe. The first patient treated in the safety expansion cohort was at the Academic Medical Center in Amsterdam by Professor Dr. Marie Jose Kersten. Additional patients are expected to be treated in multiple clinical sites across Europe in 2017. Kite has been granted access to Priority Medicines regulatory support in the EU for treatment of refractory DLBCL. Access to the PRIME initiative is granted by the EMA to support the development and accelerate the review of new therapies to treat patients with a high unmet need.

08:16 EDT Silicom awarded new Design Win for advanced FPGA - Silicom announced that one of its significant long-term customers has awarded it a new Design Win for an advanced FPGA, or Field Programmable Gate Array, based card that it will use in a new Network Visibility application. The client has already placed initial purchase orders totaling several hundred thousand dollars. In parallel, the customer, a world leader in some of the networking industry's "hottest" segments, is considering Silicom's solutions for several additional areas, including both FPGA-based and other solutions for a variety of applications.

08:13 EDT DMC completes mid-study review for Celsion's Phase III ThermoDox OPTIMA study - Celsion Corporation announced that the independent Data Monitoring Committee for the company's 550 patient, multinational, double-blind, placebo-controlled, pivotal Phase III clinical study of ThermoDox in combination with radiofrequency ablation for primary liver cancer, has completed a planned interim analysis of the first 50% of patients randomized in the trial as of April 2017 for safety and efficacy and unanimously recommended that the study continue according to protocol to its final data readout based on the risk to benefit analysis by the Committee. The OPTIMA study to date has accumulated data within acceptable safety parameters. The DMC is comprised of an independent group of medical and scientific experts and is responsible for reviewing and evaluating patient safety and efficacy data for the company's Phase III OPTIMA Study. The DMC reviews study data at regular intervals in order to ensure the safety of all patients enrolled in the trial and to monitor the quality and overall conduct of the trial including each site's compliance with the minimum RFA heating time of 45 minutes specified in the study protocol. The company also announced that enrollment in the OPTIMA Study is now over 60% of the 550 patients necessary to ensure that its primary end point, overall survival, can be achieved with statistical significance. The OPTIMA study's design and statistical plan incorporates two pre-planned interim efficacy analysis by the DMC with the intent of evaluating safety, efficacy and futility to determine if there is overwhelming evidence of clinical benefit or a low probability of treatment success to continue, modify or terminate the study. The results from the first interim efficacy analysis are expected to be made public following DMC review in Q1 of 2019.

08:10 EDT Clearside completes patient enrollment in Pivotal Phase 3 PEACHTREE trial - Clearside Biomedical announced completion of patient enrollment in the pivotal PEACHTREE clinical trial. This Phase 3 clinical trial is evaluating the safety and efficacy of CLS-TA for suprachoroidal administration, Clearside's proprietary suspension formulation of the corticosteroid triamcinolone acetonide, for the treatment of macular edema associated with non-infectious uveitis. Patient follow-up in the PEACHTREE trial is 6 months. Accordingly, Clearside currently expects to report top-line results from the trial in the first quarter of 2018. Uveitis, a set of inflammatory conditions affecting the eye, is one the world's leading causes of blindness. Uveitis occurs in about 350,000 patients in the United States and is typically found in both eyes. Macular edema occurs in approximately one-third of all non-infectious uveitis cases and is a major contributor to vision loss in these patients.

08:09 EDT Star Gas Partners, L.P. announces two acquisitions, terms not disclosed - Star Gas Partners, L.P. announced the acquisition of two businesses that further expand its customer base and, in one case, its geographic footprint. The Partnership purchased certain assets of one entity in Imlay City, Michigan and another located in Plainview, New York. The former serves approximately 3,000 accounts with annual volume of 3.8 million gallons, while the latter has roughly 16,800 accounts with annual volume of approximately 15.5 million gallons. Additional terms were not disclosed.

08:07 EDT Mylan receives tentative approval from the FDA for NDA for TLD - Mylan announced receipt of tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief for its New Drug Application, or NDA, for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 50 mg/300 mg/300 mg, or TLD. TLD, an antiretroviral, or ARV, fixed-dose combination, will be available in developing countries as a first-line regimen for people being treated for HIV/AIDS. Mylan's TLD combines molecules from three originator medicines - ViiV Healthcare's Tivicay and Epivir and Gilead Science's Viread.

08:07 EDT JMU announces strategic partnership with Century Link, TANSH - JMU announced that the company's consolidated affiliated entity in China, Shanghai Zhongmin Supply Chain Management Co., Ltd., reached a strategic partnership agreement with Hutchison Whampoa Properties Lujiazui Ltd. and TANSH Global Food Group Co., on the development of Project "Lane1192," a nearly 3,000 square-meter space designed for commercial use in Century Link, on August 1, 2017. Under the partnership, JMU and TANSH will establish a joint venture to oversee the store leasing process in the Cooperative Area and provide operating guidance and advice to its tenant shops and restaurants. TANSH will utilize its operating experience and advantages to introduce restaurant and food material brands to the Cooperative Area, and JMU will provide the integrated services of a back-end restaurant ERP system and supply chain logistics.

08:05 EDT FDA approves Medicines360's sNDA for LILETTA 52mg - Allergan and Medicines360 announced that the U.S. FDA approved Medicines360's Supplemental New Drug Application to extend the duration of use of LILETTA 52 mg for the prevention of pregnancy for up to four years.

08:04 EDT WideOpenWest appoints Tom McMillin to board - WideOpenWest announced that Tom McMillin has been appointed to the company's Board of Directors and Audit Committee, effective August 7. The appointment of McMillin increases the number of directors on the Board of Directors from seven to eight. The Board of Directors has determined that McMillin qualifies as an "independent director" as set forth in the NYSE Listed Company Manual and the Securities Exchange Act of 1934, as amended. McMillin serves as the president and COO of TierPoint and Cequel III.

08:03 EDT Teva announces FDA approval of QVAR RediHaler inahalation aerosol - Teva announced that the U.S. FDA has approved QVAR RediHaler inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older. QVAR RediHaler is not indicated for the relief of acute bronchospasm. The product is expected to become commercially available in both 40mcg and 80mcg strengths to patients by prescription during the first quarter of 2018. QVAR MDI with dose counter, the currently available form of QVAR, was originally approved by the FDA in 2014. Teva plans to discontinue sales of this current QVAR(R) MDI formulation upon the launch of QVAR RediHaler in the first quarter of 2018. Patients and caregivers are encouraged to speak with a healthcare professional about how this transition may impact their current treatment plan. This approval is supported by Teva's clinical development program for QVAR RediHaler, which includes data from one Phase I and four Phase III studies that evaluated the safety and efficacy of the product in asthma patients ages four years and older.

08:03 EDT PriceSmart reports July net warehouse club sales up 2.7% to $242.5M - PriceSmart announced that for the month of July 2017, net warehouse club sales increased 2.7% to $242.5M, from $236.3M in July a year earlier. For the eleven months ended July 31, 2017, net warehouse club sales increased 3.1% to $2.671B from $2.591B for the eleven months ended July 31, 2016. There were 39 warehouse clubs in operation at the end of July 2017 and 38 warehouse clubs in operation at the end of July 2016. For the four weeks ended July 30, 2017, comparable warehouse sales for the 38 warehouse clubs open at least 13 1/2 full months increased 1.4% compared to the same four-week period last year. For the forty-seven week period ended July 30, 2017, comparable warehouse sales increased 1.4%, compared to the comparable forty-seven week period a year ago.

08:02 EDT LiNiu Technology appoints David Wong to board of directors - LiNiu Technology Group announced that its Board of Directors has appointed David Wong as an independent director, effective immediately. Wong's appointment returns the Board to nine members, five of which are independent directors. Wong will be a member of the company's Audit Committee and Nominating and Governance Committee.

07:47 EDT Net 1 UEPS concludes investment in Cell C, DNI - Net 1 UEPS Technologies announced the completion of its 15% investment in Cell C and 45% investment in DNI-4PL Contracts. Cell C is one of the three major licensed mobile operators in South Africa with over 15 million active subscribers, and DNI is the leading distributor of mobile subscriber starter packs for Cell C, while also distributing prepaid airtime through its extensive network of field operatives and agents. Blue Label Telecoms also announced today that its investment of 45% in Cell C has been completed.

07:36 EDT Inspired Entertainment expects results to be at the bottom of previous guidance - The company said "We currently expect to be at the bottom end of our previously communicated guidance range."

07:32 EDT Charles River acquires Brains On-Line for EUR18M - Charles River Laboratories International announced that it has acquired Brains On-Line, a contract research organization providing critical data that advances novel therapeutics for the treatment of central nervous system diseases. "With operations in San Francisco, the Netherlands, and Germany, Brains On-Line is considered the world's premier provider of microdialysis for CNS research. Additionally, Brains On-Line offers sophisticated in vivo efficacy and pharmacokinetics testing to provide critical data required to advance potential CNS therapies through the development process," the company said. The purchase price was approximately EUR18M in cash, approximately $21M based on current exchange rates, subject to certain post-closing adjustments. In addition to the initial purchase price, the transaction includes potential additional payments of up to EURO6.7M based on future performance, approximately $8M based on current exchange rates.

07:32 EDT Tyson Foods says looking ahead to FY18 'with great enthusiasm' - Tyson Foods says: "We're nearing the end of a record year of earnings per share and operating income, and we're looking ahead to fiscal 2018 with great enthusiasm. We anticipate delivering another record year through differentiated capabilities, exceptionally strong brands and disciplined execution. We expect strong global demand for protein and superior focus on the fundamentals will contribute to a favorable operating environment in our Beef and Pork segments. In our Chicken segment, we will build our business through continued capacity expansion, No Antibiotics Ever and organic products, innovation and strong support of the Tyson brand. In the Prepared Foods segment, we continue to strengthen our business through improved execution in our foodservice operations, on-trend protein innovation and the integration of AdvancePierre."

07:17 EDT Kadmon non-small cell lung cancer treatment granted FDA orphan designation - Kadmon's tesevatinib was granted FDA orphan designation as a treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations, according to a post to the agency's website. Reference Link

07:16 EDT REBNY signs direct feed agreement with Move - Move, a subsidiary of News Corp and operator of realtor.com, announced that the Real Estate Board of New York has signed a direct agreement to display its Residential Listing Service's newly launched, centralized syndication feed on realtor.com, New York's fastest growing online real estate website. The agreement makes realtor.com the first major national online real estate website to receive a direct syndicated feed from REBNY, which includes the residential for-sale and rental listings from more than 600 leading New York City residential brokerage firms.

07:12 EDT Orexigen subsidiaries execute distributorship agreement in Europe for Mysimba - Orexigen Therapeutics announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland, and Cheplapharm Arzneimittel have executed a distributorship agreement covering Germany, France and Austria for Mysimba. Under the terms of the agreement, Cheplapharm will be responsible for all commercialization activity and expenses. Orexigen will supply Mysimba to Cheplapharm for a negotiated transfer price. Cheplapharm Arzneimittel GmbH is a pharmaceutical company headquartered in Greifswald, Germany with subsidiaries in France and the U.S.

07:10 EDT Bruker acquires XGLab, terms not disclosed - Bruker announced that it has acquired XGLab, a company that develops and manufactures analytical instruments for applications in the field of X-Ray spectrometry and imaging, as well as advanced electronics for X-Ray and Gamma radiation detection. Financial details of the transaction were not disclosed. XGLab will continue to operate under its current name and management, and is also looking forward to expand its read-out and signal processing OEM business with existing and additional partners.

07:09 EDT Cubic unit awarded $7.11M contract from Royal Australian Navy - Cubic Global Defense announced that Cubic Defence Australia has been selected as the primary contractor for the development and delivery of local and distributed simulation-enabled training events for the Royal Australian Navy. The four-year contract, valued at approximately $7.11M or AUD $9M, provides a wide range of simulation planning, technical support and professional interactors to enhance RAN's multisite synthetic training events at the Navy Synthetic Warfighting Centre.

07:07 EDT MyoKardia says Phase 2 PIONEER-HCM study met primary, key secondary endpoints - MyoKardia announced positive topline data from the first patient cohort of its Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy, or oHCM, patients. This cohort met the primary endpoint of change in post-exercise peak left ventricular outflow tract, or LVOT, gradient from baseline to week 12 as well as key secondary endpoints, including peak oxygen consumption, or peak VO2. Based on these results and subject to discussions in the coming months with the FDA, MyoKardia is planning for its next study, EXPLORER-HCM, to be a pivotal study. EXPLORER-HCM is expected to initiate by the end of this year. In this first patient cohort of PIONEER-HCM, 11 patients enrolled and 10 completed the study. A statistically significant improvement was observed in the primary endpoint, change in post-exercise peak LVOT gradient from baseline to week 12. After 12 weeks of treatment, all 10 subjects achieved a reduction in post-exercise peak LVOT gradient from a baseline mean of 125 mmHg. In eight of the 10 subjects, the post-exercise peak LVOT gradient was reduced below the diagnostic threshold for oHCM, with the other two patients' measurements below 50 mmHg. Clinically meaningful improvements in resting LVOT gradient were observed as early as week 2 in nine out of 10 subjects, providing the rationale for the addition of a second, low-dose cohort to the PIONEER study. Additionally, clinically and statistically significant improvements were observed in peak VO2.

07:06 EDT Can-Fite BioPharma completes human cardiodynamic safety trial for Piclidenoson - Can-Fite BioPharma announced it has successfully concluded a cardiodynamic trial for its lead drug candidate Piclidenoson. The trial is a regulatory safety requirement of both the U.S. Food and Drug Administration and the European Medicines Agency prior to the initiation of Phase III studies. Based on the favorable safety data from this cardiodynamic trial, Can-Fite is now cleared to initiate two global Phase III studies for Piclidenoson: the ACRobat trial in rheumatoid arthritis; and the Comfort trial in psoriasis. The cardiodynamic trial was a placebo-controlled crossover study using precise methodology to determine the effect of Piclidenoson on electrocardiograms of healthy volunteers. Such a study is required by U.S. and European regulatory authorities before, or in parallel with, Phase III to establish cardiac safety in humans prior to registration for marketing approval. The primary objective of the trial was to assess whether Piclidenoson causes a delay in cardiac repolarization, as manifested by prolongation of the QT interval of the electrocardiogram. A drug-induced delay in cardiac repolarization creates an electrophysiological environment that can lead to the development of ventricular cardiac arrhythmias. In this study, Piclidenoson doses were up to 3-fold higher than the highest dose expected to be used in the Company's registration-directed clinical trials. In yet another indication that Piclidenoson has a favorable human safety profile, this cardiodynamic trial showed that the Company's highest projected Piclidenoson dose had no clinically significant adverse electrocardiographic effects, thereby enabling progression into definitive Phase III trials.

07:04 EDT Gogo says on track for positive free cash flow in 2019 - Gogo said in today's earnings release, "We launched 2Ku service on five new airlines in the quarter and are on plan to meet our targeted increase in installations during the second half of the year. While these installs require up-front investment, they will all produce positive returns in the future. Our planned increase in investments in the second quarter lay the foundation for future growth in revenue and profitability. We expect Adjusted EBITDA to increase substantially in the second half of 2017 and into 2018, and we are on track to generate positive free cash flow in 2019."

07:03 EDT Marriott, Alibaba announce joint venture - Alibaba (BABA) and Marriott International (MAR) announced the establishment of a joint venture to redefine the travel experience for the hundreds of millions of Chinese consumers traveling abroad and domestically every year. The joint venture will leverage Marriott International's global portfolio of brands and unparalleled hospitality expertise to revolutionize the travel experience as well as Alibaba's digital retail leadership and its role as a gateway for international brands to reach over 500 million mobile monthly active users across its platforms. Drawing on resources from both Marriott and Alibaba, the joint venture will manage Marriott's storefront on Fliggy, Alibaba's travel service platform. It will also market directly to Alibaba's customer base, provide a link between Marriott's loyalty programs and Alibaba's loyalty program, and support Marriott hotels globally with content, programs and promotions customized for the Chinese traveler.

06:59 EDT William Lyon Homes sees FY17 revenue $1.725B-$1.8B, consensus $1.73B - The company said, "The strong performance in the first half of 2017 positions us well to achieve our goals for the year and our revised expectations for the full year include new home deliveries of approximately 3,150 to 3,350, homebuilding revenue of approximately $1.725B-$1.8B, and pre-tax income before non-controlling interest of approximately $140 million to $150 million."

06:54 EDT II-VI acquires Kaiam's 6-inch wafer fabrication facility in the U.K. for $80M - II-VI announced its acquisition of Kaiam Laser Limited, a 6-inch wafer fabrication facility in Newton Aycliffe in the United Kingdom. The purchase price of the transaction was $80M, and paid for from the company's cash reserves. The acquisition is expected to be breakeven at the EBITDA level within 12 months. The 300,000 square foot facility hosts a state of the art 100,000 square foot clean room designed for high volume manufacturing of compound semiconductor devices based on GaAs, SiC and InP materials.

06:53 EDT Digital Power: Coolisys acquires Power-Plus Technical Distributors - Digital Power announced that its wholly owned subsidiary, Coolisys Technologies, has entered a Definitive Agreement to purchase all outstanding membership interest in Power-Plus Technical Distributors, a California limited liability company. The company is purchasing Power-Plus for $850,000 of which $198,000 will be to pay off debt with the remainder to be paid out in cash over time. The Company said it anticipates the transaction to close on or around September 1.

06:51 EDT SeaWorld appoints Marc Swanson as CFO - SeaWorld Entertainment announced the appointment of Marc Swanson as CFO and Treasurer, effective immediately. Swanson had been serving in these positions on an interim basis since August 1. SeaWorld also announced the appointment of Elizabeth Gulacsy as Chief Accounting Officer, replacing Swanson. Gulacsy has served as Corporate Vice President, Financial Reporting since 2016 and Director, Financial Reporting from 2013 to 2016.

06:49 EDT Zynerba announces top-line results from Phase 2 STAR 1 trial of ZYN002 - Zynerba Pharmaceuticals announced top-line results from its double-blind placebo controlled Phase 2 STAR 1 clinical trial evaluating ZYN002 in adult epilepsy patients with focal seizures. ZYN002 did not demonstrate a statistically significant reduction of focal seizures during the treatment period compared to the baseline period for either the high or low dose cohorts compared to placebo. "We are very disappointed that the STAR 1 trial did not meet its primary endpoint in this patient population," said Armando Anido, Chairman and CEO of Zynerba. "We are continuing to evaluate this study and the ongoing STAR 2 open label study to determine next steps with ZYN002 in adult epilepsy patients with focal seizures. I'd like to thank the patients, coordinators and investigators, as well as the development team at Zynerba, for their time and energies in conducting this very important trial." Anido continued, "Importantly, today's results demonstrated ZYN002 to have a very favorable safety and tolerability profile, which is an encouraging fact as we look to develop ZYN002 as a treatment for a wide range of indications. We are excited that we will present top-line data from our ZYN002 STOP trial in osteoarthritis soon, followed by top-line data from our FAB-C study in Fragile X syndrome by the end of September."

06:46 EDT Snap-On approves $500M share repurchase program - Snap-on announced that its board of directors has authorized a share repurchase program of up to $500M of common stock that replaces two previously approved share repurchase programs under which approximately $116M of authorization remained. A third previously approved share repurchase program, which allows the repurchase of up to the number of shares issued under the company's various equity plans, remains in place. Including the new authorization, total share repurchase availability currently stands at approximately $501M.

06:34 EDT Syngenta enters into licensing agreements for Enlist E3 in soybeans - Syngenta (SYT) announced that it has entered into non-exclusive licensing agreements with Dow AgroSciences and M.S. Technologies for the Enlist E3 Event in soybeans in the U.S, Canada and Latin America, and the Conkesta Enlist E3 stack in soybeans in Latin America, with options for global rights for both. Syngenta has also entered into a non-exclusive licensing agreement with Dow AgroSciences for global rights for the Enlist event in corn. Terms of the agreement have not been disclosed. Dow AgroSciences is a wholly owned subsidiary of The Dow Chemical Company (DOW).

06:10 EDT AutoZone awarded exclusive provider contract by Houston Education Service Center - AutoZone has been awarded a multi-year contract as the exclusive provider for automotive parts and supplies by Region 4 Education Service Center, Houston, Texas. The agreement is available through the cooperative purchasing organization, National Intergovernmental Purchasing Alliance. The agreement also enables ALLDATA an AutoZone company, to offer its suite of industry-leading automotive diagnostic and repair solutions for purchase by the 48,000 public agencies and educational institutions that are National IPA participants. These agencies are eligible to purchase AutoZone parts and supplies and ALLDATA products at an agreed-upon contract price without a Request for Proposal, eliminating the laborious and time-consuming solicitation process. "AutoZone is honored to be selected as the exclusive supplier of automotive parts and accessories - and ALLDATA automotive repair technology solutions - to National IPA participating agencies," said Mitch Major, Vice President, Commercial Support, AutoZone and President, ALLDATA. "We take great pride in the confidence Region 4 and National IPA have placed in our automotive products, technology solutions, and our teams." National IPA participants include state and local government entities, educational institutions and nonprofit organizations in all 50 states, including: States and State Agencies Municipalities, Townships and Counties Public and Private Pre-K, Primary and Higher Educational Institutions and Systems Special Districts (e.g. Fire, Water, Sewer, etc.) Charitable Organizations "National IPA is thrilled the AutoZone award includes the ALLDATA solutions as a value-add to AutoZone's publicly-solicited cooperative agreement," said Ken Heckman, Senior Vice President, Account Management, National IPA. "Together, their best-in-class offering of automotive parts, service, and repair information will provide tremendous value to our participating agencies and their fleet departments."

06:07 EDT Gemphire Therapeutics reports top-line datat from ROYAL-1 Phase 2b trial - Gemphire Therapeutics announced top-line data based upon the company's preliminary review of the limited top-line data set from the completed double-blind, placebo-controlled, randomized Phase 2b ROYAL-1 trial. ROYAL-1 evaluated the efficacy, safety, and tolerability of oral gemcabene 600 mg dosed once daily. ROYAL-1 enrolled patients who were not adequately controlled, with an existing LDL-C value greater than or equal to100 mg/dL (2.59 mmol/L) and a TG value less than 500 mg/dL (5.65 mmol/L), on stable high- or moderate-intensity statin and/or ezetimibe therapy. Patients were stratified according to background statin intensity and diabetes status. One hundred and five subjects were enrolled at sites in the US and randomized to either gemcabene 600 mg or placebo for a total of 12 weeks. The primary endpoint was the percent change in LDL-C from baseline. Secondary endpoints included safety as well as the percent change from baseline in non-HDL-C, TC, TG, HDL-C, VLDL-C, Apo B, hsCRP and several other biomarkers. Fifty-six females and 49 males with a mean age of 61 years were enrolled. The mean baseline LDL-C was 130 mg/dL. Gemcabene 600 mg produced a mean percent change in LDL-C of -17.2% vs -5.5% for placebo (ANCOVA: p=0.0057). Gemcabene 600 mg produced a median percent change in hsCRP of -40.0% (ranked ANCOVA: pless than0.0001) vs -6.1% for placebo. Additional secondary results and subpopulations assessments will be provided once the full dataset has been analyzed. "In ROYAL-1, gemcabene met the primary endpoint and demonstrated a statistically significant lowering in LDL-C, although the magnitude of LDL-C lowering was less than observed in certain prior studies of gemcabene," stated Dr. Lee Golden, Chief Medical Officer. "The company will perform additional analyses to thoroughly evaluate the results of the trial. Once the additional analyses are complete, we will provide an update." There were no serious adverse events in the study. Adverse events were generally mild to moderate in intensity and consistent with previously reported AEs. Three subjects discontinued from the study, 1 from the gemcabene and 2 from the placebo groups. The subject randomized to gemcabene discontinued because of reported dizziness. No subjects in the study had a transaminase elevation greater than 3x ULN. One placebo subject had a creatine kinase elevation greater than 5x ULN on consecutive measurements. No gemcabene subjects had consecutive elevations in creatine kinase greater than 3 x ULN. The lack of liver or muscle toxicities in ROYAL-1, on top of the highest doses of statin therapy, is consistent with previous safety data from 19 prior completed studies. "The ROYAL-1 study results support gemcabene's safety profile as a potential add-on therapy to any statin intensity without signs of drug-drug interactions," added Dr. Steven Gullans, Interim CEO. "The data, in combination with previous clinical data of gemcabene, including the recently reported results of the COBALT-1 trial, will be used to plan gemcabene's future development."

06:05 EDT Investar Holding to acquire BOJ Bancshares in $22.1M transaction - Investar Holding announced that it has entered into a definitive agreement to acquire BOJ Bancshares and its wholly owned subsidiary, The Highlands Bank in Jackson, Louisiana. The transaction, which has been unanimously approved by each company's board of directors, is expected to close in the fourth quarter of 2017 and is subject to customary closing conditions, including obtaining approval by BOJ's shareholders and bank regulatory authorities. The Agreement provides for consideration to be paid to the shareholders of BOJ in the form of cash and shares of Investar common stock. Shareholders of BOJ will be entitled to receive an aggregate amount of cash consideration equal to $3.95M, subject to certain adjustments. The transaction is valued at approximately $22.1M based upon the closing price of Investar's common stock of $22.65 on August 4, 2017. Shareholders of BOJ will also be entitled to receive an aggregate of 799,559 shares of Investar common stock, subject to adjustment based upon fluctuations in Investar's average closing price for the ten consecutive trading days prior to the closing date. It is expected that shareholders of BOJ will own approximately 9% of the combined company following the acquisition. At June 30, 2017, BOJ had approximately $150M in assets, $104M in net loans, and $124M in deposits and $17M in stockholders' equity. Highlands Bank offers a full range of banking products and services to the residents of East Feliciana, West Feliciana, and East Baton Rouge Parishes through its five branch locations. Investar estimates annual pre-tax expense reductions associated with the transaction will approximate 30% of Highlands Bank's annual non-interest expenses. The expense savings are estimated to be fully achieved beginning in 2018. The transaction is expected to be immediately accretive to 2018 EPS and accretive to tangible book value at closing.

06:04 EDT BioCryst reaffirms FY17 operating expenses view $53M-$73M - Based upon development plans and our awarded government contracts, BioCryst continues to expect its 2017 net operating cash use to be in the range of $30M-$50M, and its 2017 operating expenses $53M-$73M. OPperating expense range excludes equity-based compensation expense due to the difficulty in reliably projecting this expense, as it is impacted by the volatility and price of the Company's stock, as well as by the vesting of the Company's outstanding performance-based stock options.

06:02 EDT BioCryst reports cash and equivalents and investments $95.6M at June 30 - Biocryst cash report reflects an increase from $65.1M at December 31, 2016.

05:51 EDT Biohaven completes randomization in Phase 2/3 trial of trigriluzole - Biohaven Pharmaceutical announced that it has commenced dosing of all 141 randomized patients with spinocerebellar ataxia, or SCA, in its Phase 2/3 trial of trigriluzole. As a result, Biohaven now expects to receive topline results in the fourth quarter of 2017, earlier than previously expected. Trigriluzole, a novel glutamate modulator, is a drug candidate being developed by Biohaven as a potential treatment for patients with SCA, a rare, debilitating, genetic neurodegenerative disorder that affects approximately 22,000 people in the United States. No medications are currently approved by the U.S. FDA for the treatment of this devastating condition or any other cerebellar ataxias. Trigriluzole has received both Orphan Drug Designation and Fast Track Designation for the treatment of SCA from the FDA.

05:41 EDT CrossAmerica announces pending acquisition of Jet Pep assets for $72M - CrossAmerica announced that it has entered into a definitive agreement to acquire certain assets of Holly Pond, AL based Jet Pep, Inc. for a total consideration of $72M. The assets consist of 102 commission operated retail sites, including 92 fee sites, 5 lease sites and 5 independent commission accounts. The locations sold nearly 91 million gallons of unbranded fuel in 2016. In addition, Circle K Stores, Inc., a subsidiary of Alimentation Couche-Tard and the general partner of CrossAmerica, has also agreed to purchase certain other assets from Jet Pep, Inc., including a fuel terminal, associated trucking equipment and 18 other retail sites for an undisclosed amount.